In conversation with... Marc Rothenberg

from Listen to The Lancet Gastroenterology & Hepatology · host The Lancet

Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases.

Episode metadata supplied by the publisher feed · Published Aug 10, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Marc Rothenberg

0:00 14:29

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Gastroenterology & Hepatology?

This episode is 14 minutes long.

When was this Listen to The Lancet Gastroenterology & Hepatology episode published?

This episode was published on August 10, 2023.

Can I download this Listen to The Lancet Gastroenterology & Hepatology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!